APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sustained Release Ocular Drug Delivery Systems

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Sustained Release Ocular Drug Delivery Systems Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025191 pages

Choose your research edition.

Industry ResearchSustained Release Ocular Drug Delivery Systems Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Sustained Release Ocular Drug Delivery Systems Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Sustained Release Ocular Drug Delivery Systems Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sustained Release Ocular Drug Delivery Systems Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Sustained Release Ocular Drug Delivery Systems Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Sustained Release Ocular Drug Delivery Systems market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Sustained Release Ocular Drug Delivery Systems is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Sustained Release Ocular Drug Delivery Systems is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Sustained Release Ocular Drug Delivery Systems is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Sustained Release Ocular Drug Delivery Systems is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Sustained Release Ocular Drug Delivery Systems include Aciont Inc., Allergan, Envisia Therapeutics, GrayBug, Icon Bioscience, Innocore Pharmaceuticals, Neurotech Pharmaceuticals, Ocular Therapeutix and OHR Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Sustained Release Ocular Drug Delivery Systems market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Sustained Release Ocular Drug Delivery Systems and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Sustained Release Ocular Drug Delivery Systems sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Sustained Release Ocular Drug Delivery Systems market size, projected growth trends, production technologies, key applications, and end-use industries.

Sustained Release Ocular Drug Delivery Systems Segment by Company

Aciont Inc.

Allergan

Envisia Therapeutics

GrayBug

Icon Bioscience

Innocore Pharmaceuticals

Neurotech Pharmaceuticals

Ocular Therapeutix

OHR Pharmaceuticals

PolyActiva

pSivida

TheraKine

Santen Pharmaceutical

Sustained Release Ocular Drug Delivery Systems Segment by Type

Microcapsules/Nanocapsules

Microspheres/Nanosptheres

Liposome

Implants

Sustained Release Ocular Drug Delivery Systems Segment by Application

Glaucoma

Corneal Transplantation

Cataract

Others

Sustained Release Ocular Drug Delivery Systems Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sustained Release Ocular Drug Delivery Systems market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sustained Release Ocular Drug Delivery Systems and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sustained Release Ocular Drug Delivery Systems.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Sustained Release Ocular Drug Delivery Systems market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Sustained Release Ocular Drug Delivery Systems manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Sustained Release Ocular Drug Delivery Systems in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Sustained Release Ocular Drug Delivery Systems in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Sustained Release Ocular Drug Delivery Systems Industry Trends Table 2. Sustained Release Ocular Drug Delivery Systems Industry Drivers Table 3. Sustained Release Ocular Drug Delivery Systems Industry Opportunities and Challenges Table 4. Sustained Release Ocular Drug Delivery Systems Industry Restraints Table 5. Global Sustained Release Ocular Drug Delivery Systems Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Sustained Release Ocular Drug Delivery Systems Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Manufacturers Table 9. Global Sustained Release Ocular Drug Delivery Systems Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Sustained Release Ocular Drug Delivery Systems Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Sustained Release Ocular Drug Delivery Systems Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Sustained Release Ocular Drug Delivery Systems Manufacturers, Product Type & Application Table 13. Global Sustained Release Ocular Drug Delivery Systems Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Sustained Release Ocular Drug Delivery Systems by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Microcapsules/Nanocapsules Table 17. Major Manufacturers of Microspheres/Nanosptheres Table 18. Major Manufacturers of Liposome Table 19. Major Manufacturers of Implants Table 20. Global Sustained Release Ocular Drug Delivery Systems Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 21. Global Sustained Release Ocular Drug Delivery Systems Sales by Type (2021-2026) & (W Units) Table 22. Global Sustained Release Ocular Drug Delivery Systems Sales by Type (2027-2032) & (W Units) Table 23. Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Type (2021-2026) Table 24. Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Type (2027-2032) Table 25. Global Sustained Release Ocular Drug Delivery Systems Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 26. Global Sustained Release Ocular Drug Delivery Systems Revenue by Type (2021-2026) & (W Units) Table 27. Global Sustained Release Ocular Drug Delivery Systems Revenue by Type (2027-2032) & (W Units) Table 28. Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Type (2021-2026) Table 29. Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Glaucoma Table 31. Major Manufacturers of Corneal Transplantation Table 32. Major Manufacturers of Cataract Table 33. Major Manufacturers of Others Table 34. Global Sustained Release Ocular Drug Delivery Systems Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 35. Global Sustained Release Ocular Drug Delivery Systems Sales by Application (2021-2026) & (W Units) Table 36. Global Sustained Release Ocular Drug Delivery Systems Sales by Application (2027-2032) & (W Units) Table 37. Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Application (2021-2026) Table 38. Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Application (2027-2032) Table 39. Global Sustained Release Ocular Drug Delivery Systems Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 40. Global Sustained Release Ocular Drug Delivery Systems Revenue by Application (2021-2026) & (W Units) Table 41. Global Sustained Release Ocular Drug Delivery Systems Revenue by Application (2027-2032) & (W Units) Table 42. Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Application (2021-2026) Table 43. Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Application (2027-2032) Table 44. Global Sustained Release Ocular Drug Delivery Systems Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 45. Global Sustained Release Ocular Drug Delivery Systems Sales by Region (2021-2026) & (W Units) Table 46. Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Region (2021-2026) Table 47. Global Sustained Release Ocular Drug Delivery Systems Sales Forecasted by Region (2027-2032) & (W Units) Table 48. Global Sustained Release Ocular Drug Delivery Systems Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Sustained Release Ocular Drug Delivery Systems Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 50. North America Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2026) & (W Units) Table 51. North America Sustained Release Ocular Drug Delivery Systems Sales by Country (2027-2032) & (W Units) Table 52. Europe Sustained Release Ocular Drug Delivery Systems Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 53. Europe Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2026) & (W Units) Table 54. Europe Sustained Release Ocular Drug Delivery Systems Sales by Country (2027-2032) & (W Units) Table 55. Asia Pacific Sustained Release Ocular Drug Delivery Systems Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 56. Asia Pacific Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2026) & (W Units) Table 57. Asia Pacific Sustained Release Ocular Drug Delivery Systems Sales by Country (2027-2032) & (W Units) Table 58. South America, Middle East and Africa Sustained Release Ocular Drug Delivery Systems Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 59. South America, Middle East and Africa Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2026) & (W Units) Table 60. South America, Middle East and Africa Sustained Release Ocular Drug Delivery Systems Sales by Country (2027-2032) & (W Units) Table 61. Global Sustained Release Ocular Drug Delivery Systems Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Sustained Release Ocular Drug Delivery Systems Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Sustained Release Ocular Drug Delivery Systems Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Region (2021-2026) Table 65. Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Region (2027-2032) Table 66. Aciont Inc. Company Information Table 67. Aciont Inc. Business Overview Table 68. Aciont Inc. Sustained Release Ocular Drug Delivery Systems Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Aciont Inc. Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 70. Aciont Inc. Recent Development Table 71. Allergan Company Information Table 72. Allergan Business Overview Table 73. Allergan Sustained Release Ocular Drug Delivery Systems Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Allergan Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 75. Allergan Recent Development Table 76. Envisia Therapeutics Company Information Table 77. Envisia Therapeutics Business Overview Table 78. Envisia Therapeutics Sustained Release Ocular Drug Delivery Systems Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Envisia Therapeutics Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 80. Envisia Therapeutics Recent Development Table 81. GrayBug Company Information Table 82. GrayBug Business Overview Table 83. GrayBug Sustained Release Ocular Drug Delivery Systems Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. GrayBug Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 85. GrayBug Recent Development Table 86. Icon Bioscience Company Information Table 87. Icon Bioscience Business Overview Table 88. Icon Bioscience Sustained Release Ocular Drug Delivery Systems Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Icon Bioscience Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 90. Icon Bioscience Recent Development Table 91. Innocore Pharmaceuticals Company Information Table 92. Innocore Pharmaceuticals Business Overview Table 93. Innocore Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Innocore Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 95. Innocore Pharmaceuticals Recent Development Table 96. Neurotech Pharmaceuticals Company Information Table 97. Neurotech Pharmaceuticals Business Overview Table 98. Neurotech Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Neurotech Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 100. Neurotech Pharmaceuticals Recent Development Table 101. Ocular Therapeutix Company Information Table 102. Ocular Therapeutix Business Overview Table 103. Ocular Therapeutix Sustained Release Ocular Drug Delivery Systems Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Ocular Therapeutix Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 105. Ocular Therapeutix Recent Development Table 106. OHR Pharmaceuticals Company Information Table 107. OHR Pharmaceuticals Business Overview Table 108. OHR Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. OHR Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 110. OHR Pharmaceuticals Recent Development Table 111. PolyActiva Company Information Table 112. PolyActiva Business Overview Table 113. PolyActiva Sustained Release Ocular Drug Delivery Systems Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. PolyActiva Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 115. PolyActiva Recent Development Table 116. pSivida Company Information Table 117. pSivida Business Overview Table 118. pSivida Sustained Release Ocular Drug Delivery Systems Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. pSivida Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 120. pSivida Recent Development Table 121. TheraKine Company Information Table 122. TheraKine Business Overview Table 123. TheraKine Sustained Release Ocular Drug Delivery Systems Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. TheraKine Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 125. TheraKine Recent Development Table 126. Santen Pharmaceutical Company Information Table 127. Santen Pharmaceutical Business Overview Table 128. Santen Pharmaceutical Sustained Release Ocular Drug Delivery Systems Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Santen Pharmaceutical Sustained Release Ocular Drug Delivery Systems Product Portfolio Table 130. Santen Pharmaceutical Recent Development Table 131. Key Raw Materials Table 132. Raw Materials Key Suppliers Table 133. Sustained Release Ocular Drug Delivery Systems Distributors List Table 134. Sustained Release Ocular Drug Delivery Systems Customers List Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Sustained Release Ocular Drug Delivery Systems Product Image Figure 2. Global Sustained Release Ocular Drug Delivery Systems Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Sustained Release Ocular Drug Delivery Systems Market Size (2021-2032) & (US$ Million) Figure 4. Global Sustained Release Ocular Drug Delivery Systems Sales (2021-2032) & (W Units) Figure 5. Global Sustained Release Ocular Drug Delivery Systems Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Sustained Release Ocular Drug Delivery Systems Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Microcapsules/Nanocapsules Image Figure 9. Microspheres/Nanosptheres Image Figure 10. Liposome Image Figure 11. Implants Image Figure 12. Global Sustained Release Ocular Drug Delivery Systems Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 13. Global Sustained Release Ocular Drug Delivery Systems Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Type (2021-2032) Figure 15. Global Sustained Release Ocular Drug Delivery Systems Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 16. Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Type (2021-2032) Figure 18. Glaucoma Image Figure 19. Corneal Transplantation Image Figure 20. Cataract Image Figure 21. Others Image Figure 22. Global Sustained Release Ocular Drug Delivery Systems Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global Sustained Release Ocular Drug Delivery Systems Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Application (2021-2032) Figure 25. Global Sustained Release Ocular Drug Delivery Systems Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 26. Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Application (2021-2032) Figure 28. North America Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 29. North America Sustained Release Ocular Drug Delivery Systems Sales Market Share by Country (2021-2032) Figure 30. U.S. Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 31. Canada Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Mexico Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Europe Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Europe Sustained Release Ocular Drug Delivery Systems Sales Market Share by Country (2021-2032) Figure 35. Germany Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 36. France Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 37. U.K. Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Italy Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Netherlands Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Asia Pacific Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Asia Pacific Sustained Release Ocular Drug Delivery Systems Sales Market Share by Country (2021-2032) Figure 42. China Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Japan Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 44. South Korea Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 45. Southeast Asia Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 46. India Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 47. Australia Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 48. South America, Middle East and Africa Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 49. South America, Middle East and Africa Sustained Release Ocular Drug Delivery Systems Sales Market Share by Country (2021-2032) Figure 50. Brazil Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 51. South Africa Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 52. Saudi Arabia Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Turkey Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Argentina Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 55. UAE Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Egypt Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Chile Sustained Release Ocular Drug Delivery Systems Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Global Sustained Release Ocular Drug Delivery Systems Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Sustained Release Ocular Drug Delivery Systems Revenue (2021-2032) & (US$ Million) Figure 61. North America Sustained Release Ocular Drug Delivery Systems Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Sustained Release Ocular Drug Delivery Systems Revenue (2021-2032) & (US$ Million) Figure 63. Europe Sustained Release Ocular Drug Delivery Systems Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Sustained Release Ocular Drug Delivery Systems Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Sustained Release Ocular Drug Delivery Systems Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Sustained Release Ocular Drug Delivery Systems Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Sustained Release Ocular Drug Delivery Systems Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Sustained Release Ocular Drug Delivery Systems Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Sustained Release Ocular Drug Delivery Systems Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Microcapsules/Nanocapsules
  • Microspheres/Nanosptheres
  • Liposome
  • Implants
Applications
  • Glaucoma
  • Corneal Transplantation
  • Cataract
  • Others
Companies covered
  • Aciont Inc.
  • Allergan
  • Envisia Therapeutics
  • GrayBug
  • Icon Bioscience
  • Innocore Pharmaceuticals
  • Neurotech Pharmaceuticals
  • Ocular Therapeutix
  • OHR Pharmaceuticals
  • PolyActiva
  • pSivida
  • TheraKine
  • Santen Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Sustained Release Ocular Drug Delivery Systems Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Sustained Release Ocular Drug Delivery Systems Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Sustained Release Ocular Drug Delivery Systems Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Sustained Release Ocular Drug Delivery Systems Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Sustained Release Ocular Drug Delivery Systems Market Dynamics
  1. 2.1 Sustained Release Ocular Drug Delivery Systems Industry Trends
  2. 2.2 Sustained Release Ocular Drug Delivery Systems Industry Drivers
  3. 2.3 Sustained Release Ocular Drug Delivery Systems Industry Opportunities and Challenges
  4. 2.4 Sustained Release Ocular Drug Delivery Systems Industry Restraints
3 Sustained Release Ocular Drug Delivery Systems Market by Manufacturers
  1. 3.1 Global Sustained Release Ocular Drug Delivery Systems Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Sustained Release Ocular Drug Delivery Systems Sales by Manufacturers (2021-2026)
  3. 3.3 Global Sustained Release Ocular Drug Delivery Systems Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Sustained Release Ocular Drug Delivery Systems Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Sustained Release Ocular Drug Delivery Systems Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Sustained Release Ocular Drug Delivery Systems Manufacturers, Product Type & Application
  7. 3.7 Global Sustained Release Ocular Drug Delivery Systems Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Sustained Release Ocular Drug Delivery Systems Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Sustained Release Ocular Drug Delivery Systems Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Sustained Release Ocular Drug Delivery Systems Tier 1, Tier 2, and Tier 3
4 Sustained Release Ocular Drug Delivery Systems Market by Type
  1. 4.1 Sustained Release Ocular Drug Delivery Systems Type Introduction
  2. 4.1.1 Microcapsules/Nanocapsules
  3. 4.1.2 Microspheres/Nanosptheres
  4. 4.1.3 Liposome
  5. 4.1.4 Implants
  6. 4.2 Global Sustained Release Ocular Drug Delivery Systems Sales by Type
  7. 4.2.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Sustained Release Ocular Drug Delivery Systems Sales by Type (2021-2032)
  9. 4.2.3 Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Type (2021-2032)
  10. 4.3 Global Sustained Release Ocular Drug Delivery Systems Revenue by Type
  11. 4.3.1 Global Sustained Release Ocular Drug Delivery Systems Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Sustained Release Ocular Drug Delivery Systems Revenue by Type (2021-2032)
  13. 4.3.3 Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Type (2021-2032)
5 Sustained Release Ocular Drug Delivery Systems Market by Application
  1. 5.1 Sustained Release Ocular Drug Delivery Systems Application Introduction
  2. 5.1.1 Glaucoma
  3. 5.1.2 Corneal Transplantation
  4. 5.1.3 Cataract
  5. 5.1.4 Others
  6. 5.2 Global Sustained Release Ocular Drug Delivery Systems Sales by Application
  7. 5.2.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Sustained Release Ocular Drug Delivery Systems Sales by Application (2021-2032)
  9. 5.2.3 Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Application (2021-2032)
  10. 5.3 Global Sustained Release Ocular Drug Delivery Systems Revenue by Application
  11. 5.3.1 Global Sustained Release Ocular Drug Delivery Systems Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Sustained Release Ocular Drug Delivery Systems Revenue by Application (2021-2032)
  13. 5.3.3 Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Application (2021-2032)
6 Global Sustained Release Ocular Drug Delivery Systems Sales by Region
  1. 6.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Sustained Release Ocular Drug Delivery Systems Sales by Region (2021-2032)
  3. 6.2.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Region (2021-2026)
  4. 6.2.2 Global Sustained Release Ocular Drug Delivery Systems Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Sustained Release Ocular Drug Delivery Systems Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Sustained Release Ocular Drug Delivery Systems Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Sustained Release Ocular Drug Delivery Systems Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Sustained Release Ocular Drug Delivery Systems Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Sustained Release Ocular Drug Delivery Systems Revenue by Region
  1. 7.1 Global Sustained Release Ocular Drug Delivery Systems Revenue by Region
  2. 7.1.1 Global Sustained Release Ocular Drug Delivery Systems Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Sustained Release Ocular Drug Delivery Systems Revenue by Region (2021-2026)
  4. 7.1.3 Global Sustained Release Ocular Drug Delivery Systems Revenue by Region (2027-2032)
  5. 7.1.4 Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Sustained Release Ocular Drug Delivery Systems Revenue (2021-2032)
  8. 7.2.2 North America Sustained Release Ocular Drug Delivery Systems Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Sustained Release Ocular Drug Delivery Systems Revenue (2021-2032)
  11. 7.3.2 Europe Sustained Release Ocular Drug Delivery Systems Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Sustained Release Ocular Drug Delivery Systems Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Sustained Release Ocular Drug Delivery Systems Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Sustained Release Ocular Drug Delivery Systems Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Sustained Release Ocular Drug Delivery Systems Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Aciont Inc.
  2. 8.1.1 Aciont Inc. Company Information
  3. 8.1.2 Aciont Inc. Business Overview
  4. 8.1.3 Aciont Inc. Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Aciont Inc. Sustained Release Ocular Drug Delivery Systems Product Portfolio
  6. 8.1.5 Aciont Inc. Recent Developments
  7. 8.2 Allergan
  8. 8.2.1 Allergan Company Information
  9. 8.2.2 Allergan Business Overview
  10. 8.2.3 Allergan Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Allergan Sustained Release Ocular Drug Delivery Systems Product Portfolio
  12. 8.2.5 Allergan Recent Developments
  13. 8.3 Envisia Therapeutics
  14. 8.3.1 Envisia Therapeutics Company Information
  15. 8.3.2 Envisia Therapeutics Business Overview
  16. 8.3.3 Envisia Therapeutics Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Envisia Therapeutics Sustained Release Ocular Drug Delivery Systems Product Portfolio
  18. 8.3.5 Envisia Therapeutics Recent Developments
  19. 8.4 GrayBug
  20. 8.4.1 GrayBug Company Information
  21. 8.4.2 GrayBug Business Overview
  22. 8.4.3 GrayBug Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GrayBug Sustained Release Ocular Drug Delivery Systems Product Portfolio
  24. 8.4.5 GrayBug Recent Developments
  25. 8.5 Icon Bioscience
  26. 8.5.1 Icon Bioscience Company Information
  27. 8.5.2 Icon Bioscience Business Overview
  28. 8.5.3 Icon Bioscience Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Icon Bioscience Sustained Release Ocular Drug Delivery Systems Product Portfolio
  30. 8.5.5 Icon Bioscience Recent Developments
  31. 8.6 Innocore Pharmaceuticals
  32. 8.6.1 Innocore Pharmaceuticals Company Information
  33. 8.6.2 Innocore Pharmaceuticals Business Overview
  34. 8.6.3 Innocore Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Innocore Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio
  36. 8.6.5 Innocore Pharmaceuticals Recent Developments
  37. 8.7 Neurotech Pharmaceuticals
  38. 8.7.1 Neurotech Pharmaceuticals Company Information
  39. 8.7.2 Neurotech Pharmaceuticals Business Overview
  40. 8.7.3 Neurotech Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Neurotech Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio
  42. 8.7.5 Neurotech Pharmaceuticals Recent Developments
  43. 8.8 Ocular Therapeutix
  44. 8.8.1 Ocular Therapeutix Company Information
  45. 8.8.2 Ocular Therapeutix Business Overview
  46. 8.8.3 Ocular Therapeutix Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Ocular Therapeutix Sustained Release Ocular Drug Delivery Systems Product Portfolio
  48. 8.8.5 Ocular Therapeutix Recent Developments
  49. 8.9 OHR Pharmaceuticals
  50. 8.9.1 OHR Pharmaceuticals Company Information
  51. 8.9.2 OHR Pharmaceuticals Business Overview
  52. 8.9.3 OHR Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 OHR Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio
  54. 8.9.5 OHR Pharmaceuticals Recent Developments
  55. 8.10 PolyActiva
  56. 8.10.1 PolyActiva Company Information
  57. 8.10.2 PolyActiva Business Overview
  58. 8.10.3 PolyActiva Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 PolyActiva Sustained Release Ocular Drug Delivery Systems Product Portfolio
  60. 8.10.5 PolyActiva Recent Developments
  61. 8.11 pSivida
  62. 8.11.1 pSivida Company Information
  63. 8.11.2 pSivida Business Overview
  64. 8.11.3 pSivida Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 pSivida Sustained Release Ocular Drug Delivery Systems Product Portfolio
  66. 8.11.5 pSivida Recent Developments
  67. 8.12 TheraKine
  68. 8.12.1 TheraKine Company Information
  69. 8.12.2 TheraKine Business Overview
  70. 8.12.3 TheraKine Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 TheraKine Sustained Release Ocular Drug Delivery Systems Product Portfolio
  72. 8.12.5 TheraKine Recent Developments
  73. 8.13 Santen Pharmaceutical
  74. 8.13.1 Santen Pharmaceutical Company Information
  75. 8.13.2 Santen Pharmaceutical Business Overview
  76. 8.13.3 Santen Pharmaceutical Sustained Release Ocular Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Santen Pharmaceutical Sustained Release Ocular Drug Delivery Systems Product Portfolio
  78. 8.13.5 Santen Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Sustained Release Ocular Drug Delivery Systems Value Chain Analysis
  2. 9.1.1 Sustained Release Ocular Drug Delivery Systems Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Sustained Release Ocular Drug Delivery Systems Production Mode & Process
  6. 9.2 Sustained Release Ocular Drug Delivery Systems Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Sustained Release Ocular Drug Delivery Systems Distributors
  9. 9.2.3 Sustained Release Ocular Drug Delivery Systems Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst